Previous 10 | Next 10 |
FY2020 till date has seen 127 SPAC IPOs, which collectively raised over $48.5B in proceeds, much more than the past ten years combined.Going public via a SPACs is a cost-effective way of doing an M&A deal in weeks instead of months, and its proving to be an especially attractive vehi...
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- 180 Life Sciences Corp. today announces its placement in an editorial published by Network NewsWire ("NNW"), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and ...
180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) and will be l...
180 Life Sciences , a clinical-stage biotechnology company, is focused on the development of novel drugs that fulfill unmet needs for a variety of conditions including fibrosis, pain and inflammatory diseases. 180 Life Sciences will soon form a combined company with KBL Merger Corp. IV (NASDA...
180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value The company has a large and expanding patent portfolio The risks associated with the company’s drug developme...
IPOs are the past The casting couch... Outer borough pit traders with a feeling about how to price some options... A baseball player’s rugged jawline: Every industry had their pre- Moneyball ways of making choices based on favors, hunches, and biases. People did things that w...
KBL Merger Corp. (NASDAQ: KBLM), a special purpose acquisition corporation (“SPAC”) that previously announced the signing of a definitive agreement to acquire CannBioRx Life Sciences Corp. (now to be referred to as "180 Life Sciences"), on Monday announced successful closing of a...
NEW YORK , June 29, 2020 /PRNewswire/ -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition corporation (SPAC) that previously announced the signing of a definitive agreement to acquire CannBioRx Life Sciences Corp. (now to be referred to as "180 Lif...
NEW YORK , July 26, 2019 /PRNewswire/ -- KBL Merger Corp. IV (NASDAQ: KBLM) ("KBLM"), a Special Purpose Acquisition Company (SPAC), announced today that it has executed a definitive business combination agreement for the merger of a wholly owned subsidiary of KBLM with CannBioRx Life Scie...
NEW YORK , May 14, 2019 /PRNewswire/ -- KBL Merger Corp. IV ("KBL" or "the Company") (NASDAQ: KBLM), a special purpose acquisition corporation, or SPAC, that completed its IPO in June 2017 , announced today that it has entered into a non-binding term sheet to acquire CannBioRx Life ...
News, Short Squeeze, Breakout and More Instantly...
KBL Merger IV Company Name:
KBLM Stock Symbol:
NASDAQ Market:
Combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early cancer detection, diagnostic insights, and targeted immunotherapies The decision to join forces resulted from a carefully considered strategy to combine strengths ...
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC), today announced the successful completion of its acquisition of 180 Life Sciences Corp. ("180 Life Sciences"), a clinical-stage biote...
NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire 180 Life Sciences Corp. ("180 Life Sciences"), today announced that a special meetin...